These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15977965)

  • 1. Enoxaparin versus heparin: the SYNERGY trial from an emergency medicine perspective.
    Rokos IC
    Drugs; 2005; 65(10):1313-6. PubMed ID: 15977965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
    JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective.
    Balen RM; Marra CA; Zed PJ; Cohen M; Frighetto L
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):533-42. PubMed ID: 10662478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
    Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
    Montalescot G; Zeymer U; Silvain J; Boulanger B; Cohen M; Goldstein P; Ecollan P; Combes X; Huber K; Pollack C; Bénezet JF; Stibbe O; Filippi E; Teiger E; Cayla G; Elhadad S; Adnet F; Chouihed T; Gallula S; Greffet A; Aout M; Collet JP; Vicaut E;
    Lancet; 2011 Aug; 378(9792):693-703. PubMed ID: 21856483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.
    Orlewska E; Budaj A; Tereszkowski-Kaminski D
    Pharmacoeconomics; 2003; 21(10):737-48. PubMed ID: 12828495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.
    Goodman S
    Am Heart J; 2005 Apr; 149(4 Suppl):S73-80. PubMed ID: 16124951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.
    Coons JC; Battistone S
    Ann Pharmacother; 2008 Jul; 42(7):989-1001. PubMed ID: 18577763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
    JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of postrandomization crossover of therapy in acute coronary syndromes care.
    Mahaffey KW; Pieper KS; Lokhnygina Y; Califf RM; Antman EM; Kleiman NS; Goodman SG; White HD; Rao SV; Hochman JS; Cohen M; Col JJ; Roe MT; Ferguson JJ;
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):211-9. PubMed ID: 21304094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of enoxaparin in interventional management of patients with acute coronary syndromes.
    Grines CL; O'Neill W
    J Interv Cardiol; 2003 Oct; 16(5):357-66. PubMed ID: 14603790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
    Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
    Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enoxaparin failed to show superiority to unfractionated heparin in patients with non ST-elevation acute coronary syndrome in a phase of A to Z trial].
    Gratsianskiĭ NA
    Kardiologiia; 2003; 43(6):70-1. PubMed ID: 12974259
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome.
    Brosa M; Rubio-Terrés C; Farr I; Nadipelli V; Froufe J
    Pharmacoeconomics; 2002; 20(14):979-87. PubMed ID: 12403638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?
    Wolak A; Ayzenberg Y; Cafri C; Gilutz H; Ilia R; Zahger D
    Int J Cardiol; 2004 Aug; 96(2):151-5. PubMed ID: 15262028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.